(MBX) MBX Biosciences, Common - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 1.557m USD | Total Return: 154.6% in 12m
Avg Turnover: 19.1M
Warnings
Share dilution 39.4% YoY
High Debt while negative Cash Flow
Altman Z'' -14.82 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
Confidence
MBX Biosciences, Inc. is a clinical-stage biopharmaceutical firm headquartered in Indiana, specializing in precision peptide therapies for endocrine and metabolic disorders. The company’s pipeline is led by Canvuparatide (MBX 2109), currently in Phase 3 clinical trials for chronic hypoparathyroidism, alongside Phase 2 and preclinical candidates targeting post-bariatric hypoglycemia and obesity.
The biotechnology sector often utilizes prodrug technology to improve the pharmacokinetic profiles of peptides, aiming to reduce dosing frequency and improve patient adherence. MBX follows a high-research-intensity business model common among clinical-stage firms, where value is primarily derived from the progression of proprietary candidates through the FDA regulatory approval pipeline.
Investors can evaluate the long-term risk-reward profile of this clinical pipeline by reviewing the data on ValueRay. Founded in 2018, the company focuses on addressing metabolic co-morbidities through long-acting receptor antagonists and hormone analogs.
- Canvuparatide Phase 3 clinical trial results determine primary pathway to commercial revenue
- FDA regulatory approval timeline for MBX 2109 impacts long-term valuation
- Clinical advancement of Imapextide Phase 2 trials drives metabolic disorder market positioning
- Early-stage development of MBX 4291 influences competitiveness in the high-growth obesity sector
- Capital expenditure and cash burn rates dictate future equity financing requirements
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.18 > 0.02 and ΔFCF/TA 9.73 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.17 > 3% & CFO -77.5m > Net Income -86.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 30.79 > 1.5 & < 3 |
| Outstanding Shares: last quarter (46.6m) vs 12m ago 39.40% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.09%; Δ -0.09% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
| A: 0.96 (Total Current Assets 448.5m - Total Current Liabilities 14.6m) / Total Assets 452.7m |
| B: -0.55 (Retained Earnings -248.0m / Total Assets 452.7m) |
| C: -0.28 (EBIT TTM -96.5m / Avg Total Assets 349.3m) |
| D: -16.63 (Book Value of Equity -248.6m / Total Liabilities 14.9m) |
| Altman-Z'' = -14.82 = D |
As of May 24, 2026, the stock is trading at USD 31.79 with a total of 455,483 shares traded.
Over the past week, the price has changed by -1.85%,
over one month by -5.15%,
over three months by -13.33% and
over the past year by +154.60%.
MBX Biosciences, Common has received a consensus analysts rating of 4.60. Therefore, it is recommended to buy MBX.
- StrongBuy: 3
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 69.1 | 117.3% |
Revenue TTM = 0.0 USD
EBIT TTM = -96.5m USD
EBITDA TTM = -96.3m USD
Long Term Debt = 377k USD (estimated: total debt 555k - short term 178k)
Short Term Debt = 178k USD (from shortTermDebt, last quarter)
Debt = 555k USD (from shortLongTermDebtTotal, last quarter) (leases 555k already included)
Net Debt = -439.4m USD (calculated: Debt 555k - CCE 440.0m)
Enterprise Value = 1.12b USD (1.56b + Debt 555k - CCE 440.0m)
Interest Coverage Ratio = unknown (Ebit TTM -96.5m / Interest Expense TTM 0.0)
EV/FCF = -14.01x (Enterprise Value 1.12b / FCF TTM -79.8m)
FCF Yield = -7.14% (FCF TTM -79.8m / Enterprise Value 1.12b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 324k) / Revenue TTM)
Tobins Q-Ratio = 2.47 (Enterprise Value 1.12b / Total Assets 452.7m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 555k)
Taxrate = 21.0% (US default 21%)
NOPAT = -76.3m (EBIT -96.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 30.79 (Total Current Assets 448.5m / Total Current Liabilities 14.6m)
Debt / Equity = 0.00 (Debt 555k / totalStockholderEquity, last quarter 437.8m)
Debt / EBITDA = 4.56 (negative EBITDA) (Net Debt -439.4m / EBITDA -96.3m)
Debt / FCF = 5.51 (negative FCF - burning cash) (Net Debt -439.4m / FCF TTM -79.8m)
Total Stockholder Equity = 353.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -24.79% (Net Income -86.6m / Total Assets 452.7m)
RoE = -14.40% (Net Income TTM -86.6m / Total Stockholder Equity 601.4m)
RoCE = -16.04% (EBIT -96.5m / Capital Employed (Equity 601.4m + L.T.Debt 377k))
RoIC = -18.19% (negative operating profit) (NOPAT -76.3m / Invested Capital 419.3m)
WACC = 12.77% (E(1.56b)/V(1.56b) * Re(12.77%) + D(555k)/V(1.56b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 12.77% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 97.75 | Cagr: 18.40%
[DCF] Fair Price = unknown (Cash Flow -79.8m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.02 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.60 | Chg30d=+5.89% | Revisions=+60% | Analysts=8
EPS next Quarter (2026-09-30): EPS=-0.74 | Chg30d=+2.38% | Revisions=+33% | Analysts=8
EPS current Year (2026-12-31): EPS=-2.75 | Chg30d=+4.97% | Revisions=+38% | GrowthEPS=-15.5% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-3.94 | Chg30d=+2.92% | Revisions=+17% | GrowthEPS=-43.5% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +60%